公开(公告)号：EP2540720B1

公开(公告)日：2015-04-15

申请号：EP11747546.7

申请日：2011-02-25

申请人： Japan Tobacco, Inc.

发明人： MIYAZAKI, Susumu ,  BESSHO, Yuki ,  ADACHI, Kaoru ,  KAWASHITA, Seiji ,  ISOSHIMA, Hirotaka ,  OSHITA, Kengo ,  FUKUDA, Shunichi

IPC分类号： C07D471/04 ,  A61K31/4985 ,  A61K31/5377 ,  A61P31/18 ,  A61P43/00

CPC分类号： C07D471/04 ,  A61K31/4985 ,  A61K31/5377

公开(公告)号：EP4397663A1

公开(公告)日：2024-07-10

申请号：EP22864569.3

申请日：2022-08-30

申请人： Japan Tobacco, Inc.

发明人： OHBA, Yusuke ,  ADACHI, Kaoru ,  NISHIMARU, Tatsuya ,  SAKURAI, Kentaro ,  OGOSHI, Yosuke ,  SATO, Shimpei

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/00 ,  A61P9/00 ,  A61P9/10 ,  A61P13/12 ,  A61P17/00 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P25/28

CPC分类号： A61K31/519 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/00 ,  A61P9/00 ,  A61P9/10 ,  A61P13/12 ,  A61P17/00 ,  A61P19/02 ,  A61P19/06 ,  A61P21/02 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P27/04 ,  A61P29/00 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07D487/04 ,  C07D519/00

摘要： A 6-aminopyrazolopyrimidine compound, or a pharmaceutically acceptable salt thereof, having NLRP3 inflammasome inhibitory activity, a pharmaceutical composition comprising the same, and their medical use, etc., are provided.
A compound of Formula [IA]:

or a pharmaceutically acceptable salt thereof,
wherein a partial structure:

is a structure of the following formula:

etc.
wherein R4 is hydrogen or C1-4 alkyl, in which the alkyl may be optionally substituted with hydroxy or cyano,
Ring group CyA is a group of the following formula:

etc.
wherein R6 and R7 are, each independently, hydrogen, hydroxy, cyano, C1-6 alkyl, etc., R8 and R9 are, each independently, hydrogen, C1-4 alkyl, or C1-4 haloalkyl, R10 is hydrogen, cyano, C1-6 alkyl, etc.),
R1 is hydrogen or C1-4 alkyl,
R2A and R3A are, each independently, hydrogen, C1-6 alkyl etc., alternatively, R2A and R3A may combine together with the nitrogen atom to which they attach and the -NR2AR3A group may form a 4- to 7-membered optionally-substituted heterocycloalkyl, etc.

公开(公告)号：EP4082614A1

公开(公告)日：2022-11-02

申请号：EP20905600.1

申请日：2020-12-25

申请人： Japan Tobacco Inc.

发明人： OHBA, Yusuke ,  FURUKAWA, Takayuki ,  ADACHI, Kaoru ,  NISHIMARU, Tatsuya ,  SAKURAI, Kentaro ,  MASUO, Ritsuki ,  INAMI, Tasuku

IPC分类号： A61P13/12 ,  A61P25/00 ,  A61P43/00 ,  C07D413/12 ,  C07D413/14 ,  C07D491/048 ,  C07D491/107 ,  C07D263/48 ,  C07D487/04 ,  C07D487/08 ,  C07D498/08 ,  C07D498/10 ,  A61K31/421 ,  A61K31/422 ,  A61K31/454 ,  A61K31/496 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/553

摘要： An acylsulfamide compound, or a pharmaceutically acceptable salt thereof, having NLRP3 inflammasome inhibitory activity, a pharmaceutical composition comprising the same, and their medical use, etc., are provided.
A compound of Formula [Ia]:

or a pharmaceutically acceptable salt thereof, wherein
a partial structure:

is:
Ring Cy is an optionally substituted heteroaryl or phenyl;
R Dy and R Ey are each independently hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 1-4 haloalkyl, optionally substituted C 3-6 cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl, or alternatively, R Dy and R Ey may combine together with the nitrogen atom to which they attach to form heterocycloalkyl, etc.

公开(公告)号：EP2540720A1

公开(公告)日：2013-01-02

申请号：EP11747546.7

申请日：2011-02-25

申请人： Japan Tobacco, Inc.

发明人： MIYAZAKI, Susumu ,  BESSHO, Yuki ,  ADACHI, Kaoru ,  KAWASHITA, Seiji ,  ISOSHIMA, Hirotaka ,  OSHITA, Kengo ,  FUKUDA, Shunichi

IPC分类号： C07D471/04 ,  A61K31/4985 ,  A61K31/5377 ,  A61P31/18 ,  A61P43/00

CPC分类号： C07D471/04 ,  A61K31/4985 ,  A61K31/5377

摘要： Provided is a novel 1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine derivative or a pharmaceutically acceptable salt thereof, or a solvate thereof, which is useful as an anti-HIV agent.
The present invention provides a compound represented by the following formula [I]

wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

摘要翻译： 提供了可用作抗HIV剂的新的1,3,4,8-四氢-2H-吡啶并[1,2-a]吡嗪衍生物或其药学上可接受的盐或其溶剂合物。 本发明提供由下式[I]表示的化合物，其中每个符号如说明书中所定义，或其药学上可接受的盐或其溶剂合物。